Status:
Ready to upload
Record number:
1767
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Common. About 8% of first time RBC transfused patients will form a red cell alloantibody. This randomized prospective trial compares antibody formation rate of standard vs extended serologic matching, observing about 2/3 reduction in antibody formation rate with extended panel matched RBC transfusion, but only in patients not receiving platelets.
Time to detection:
Delayed over months following the transfusion.
Alerting signals, symptoms, evidence of occurrence:
Delayed serologic reactions, presence of a newly formed alloantibody
Demonstration of imputability or root cause:
RBC alloantibodies being formed to discordant antigens (antigens on red cells not present in the recipient)
Imputability grade:
3 Definite/Certain/Proven
Groups audience:
Keywords:
Suggest new keywords:
RBC alloantibody formation, extended serologic matching
Reference attachment:
Suggest references:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Incidence+of+alloantibody+formation+after+ABO-D+or+extended+matched+red+blood+cell+transfusions%3A+a+randomized+trial+%28MATCH+study%29
Expert comments for publication:
Study demonstrates that extended matching of RBCs, beyond ABO-D in patients not also receiving platelets, can reduce the development of RBC alloantibodies.